J9601 HCPCS Level II code: Injection, linvoseltamab-gcpt, 1 mg
J9601 is the HCPCS code for “Injection, linvoseltamab-gcpt, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9601Injection, linvoseltamab-gcpt, 1 mg
Short description: Inj linvoseltamab-gcpt 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9601 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Apr 1, 2026
Where J9601 sits
- 1J codesDrugs administered other than orally
- 2Active code J9601Injection, linvoseltamab-gcpt, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9601 mean?
J9601 is the HCPCS code for “Injection, linvoseltamab-gcpt, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9601?
CMS lists J9601’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9601
All J codesJ9390Injection, vinorelbine tartrate, 10 mgJ9393Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mgJ9394Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mgJ9395Injection, fulvestrant, 25 mgJ9400Injection, ziv-aflibercept, 1 mgJ9600Injection, porfimer sodium, 75 mgJ9999Not otherwise classified, antineoplastic drugs